Off-Target Based Drug Repurposing Opportunities for Tivantinib in Acute Myeloid Leukemia

Scientific Reports - United Kingdom
doi 10.1038/s41598-018-37174-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Drug Repurposing for the Treatment of Acute Myeloid Leukemia

Frontiers in Medicine
Medicine
2017English

The Role of TP53 in Acute Myeloid Leukemia: Challenges and Opportunities

Genes Chromosomes and Cancer
Cancer ResearchGenetics
2019English

Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia

PLoS ONE
Multidisciplinary
2013English

Acute Myeloid Leukemia Drug Development in the Post‐Venetoclax Era

American Journal of Hematology
Hematology
2019English

Oligonucleotide Aptamer-Drug Conjugates for Targeted Therapy of Acute Myeloid Leukemia

Biomaterials
Mechanics of MaterialsBiophysicsBiomaterialsBioengineeringCompositesNanoscienceNanotechnologyCeramics
2015English

Acute Myeloid Leukemia

JAMA - Journal of the American Medical Association
Medicine
2010English

Acute Myeloid Leukemia

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

Cranberry A-Type Proanthocyanidins Selectively Target Acute Myeloid Leukemia Cells

Blood advances
Hematology
2019English

Emerging Therapies for Acute Myeloid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy